难治性葡萄膜炎每周阿达木单抗治疗成功的预测因素:一项回顾性队列研究
本回顾性队列研究在单中心学术机构纳入非感染性葡萄膜炎患者,这些患者在每两周阿达木单抗治疗下控制不佳或复发而需剂量升级或调整治疗。检测抗阿达木单抗抗体且结果为低至中等水平的患者,与升级前未检测抗体的患者相比,升级后治疗成功率更高(HR 2.63,95%CI 1.09-6.37,P=0.031)。在全队列中,全葡萄膜炎患者(n=14)较前葡萄膜炎参照组(n=26)治疗成功率更低(HR 0.09,95%CI 0.01-0.99,P=0.05)。
要点
- 抗阿达木单抗抗体低至中等水平组升级后治疗成功率的HR为2.63(95%CI 1.09-6.37,P=0.031),高于未检测抗体组。
- 全葡萄膜炎患者(n=14)较前葡萄膜炎患者(n=26)升级后治疗成功率更低,HR为0.09(95%CI 0.01-0.99,P=0.05)。
- 作者认为升级前检测抗阿达木单抗抗体可能有临床价值,低水平抗体可能带来成功优势。
核心结论
- 抗阿达木单抗抗体低至中等水平的患者,升级后治疗成功率高于未检测抗体的患者,提示升级前检测抗体可能有价值,低水平抗体可能带来成功优势。
- 全葡萄膜炎患者升级后治疗成功率较低,而前葡萄膜炎患者治疗成功率很高,提示某些疾病特征可能指导临床医生决定升级还是更换治疗。
研究设计与样本
- 回顾性临床队列研究,在单中心学术机构开展。
- 研究对象为每两周阿达木单抗治疗下控制不佳或出现疾病复发、需要剂量升级或调整治疗的非感染性葡萄膜炎患者。
- 检测抗阿达木单抗抗体且结果为低至中等水平的患者(n=24)与升级前未检测抗体的患者(n=41)进行比较;检测结果为高水平的患者未进行升级。
- 采用Kaplan-Meier生存分析和Cox比例风险模型分析升级成功的预测因素及升级前抗体检测的效用。
主要发现
- 抗阿达木单抗抗体低至中等水平组(n=24,平均32.3 ng/mL,范围0-154 ng/mL)升级后治疗成功率高于未检测抗体组(n=41),HR为2.63(标准误1.19,95%CI 1.09-6.37,P=0.031)。
- 全队列中全葡萄膜炎患者(n=14)较前葡萄膜炎参照组(n=26)治疗成功率更低,HR为0.09(标准误0.11,95%CI 0.01-0.99,P=0.05)。
关键数值与推荐
- 治疗成功定义为前房炎症细胞分级≤0.5+、局部糖皮质激素≤1滴/天、口服泼尼松≤5 mg/天、黄斑水肿消退、血管造影炎症征象消退,且未增加或升级任何治疗。
- 抗阿达木单抗抗体低至中等水平组平均32.3 ng/mL,范围0-154 ng/mL(n=24)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine predictors of treatment success after dose escalation of adalimumab, including the measurement of anti-adalimumab antibodies as a predictor of success. DESIGN: Retrospective clinical cohort study. METHODS: Setting: Single-center academic institution. STUDY POPULATION: Patients with noninfectious uveitis who were inadequately controlled or developed recurrent disease on every other week adalimumab and required dose escalation or therapy modification. OBSERVATION PROCEDURES: Patients who had anti-adalimumab antibodies checked with resultant low to intermediate levels were compared with patients who had no testing performed before adalimumab dose escalation. Of note, patients with testing and resultant high levels of anti-adalimumab antibodies were not escalated. Predictors of escalation success and utility of antibody testing before escalation were analyzed using Kaplan-Meier survival analysis and Cox proportional hazards models. MAIN OUTCOME MEASURES: Treatment success defined as anterior chamber grade ≤0.5+ cell, topical corticosteroids ≤1 drop/d, oral prednisone ≤5 mg/d, resolution of macular edema, and resolution of angiographic signs of inflammation without any addition or escalation of therapy. RESULTS: A total of 24 patients had antibodies tested with low to intermediate levels (average: 32.3 ng/mL, range: 0-154 ng/mL), whereas 41 did not have antibody testing. A greater treatment success rate after escalation was observed among the "low antibody" group compared with the "no testing" group (hazard ratio: 2.63, standard error: 1.19, P = .031, 95% CI: 1.09-6.37). Among the entire cohort, patients with panuveitis (n = 14) had a lower treatment success rate compared with the reference of anterior uveitis (n = 26) (hazard ratio: 0.09, standard error: 0.11, P = .05, 95% CI: 0.01-0.99). CONCLUSIONS: Patients with low anti-adalimumab antibodies had a greater treatment success than patients in whom antibodies were not checked. This suggests a utility to checking antibodies before dose escalation and that low levels of antibodies may confer a success advantage. Overall, patients with panuveitis had a lower rate of success after escalation while patients with anterior uveitis patients had a very high rate of success suggesting that certain disease characteristics may guide clinicians when determining who to escalate versus changing therapy.
引用
- Janetos TM, Kanwar K, Bashey S, et al. Predictors of Therapy Success in Weekly Adalimumab for Refractory Uveitis: A Retrospective Cohort Study. Am J Ophthalmol. 2024. PMID: 39033832. doi:10.1016/j.ajo.2024.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。